Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 33.3%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 0 · 0%

Remdesivir and standard care vs placebo or usual care

All‐cause mortality at up to day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Remdesivir for the treatment of COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.85 [0.69, 1.05]
1 study · 1281 participants
Moderate

Remdesivir and standard care vs placebo or usual care

All‐cause mortality at up to day 28 · non‐hospitalised adults with mild COVID‐19

1 finding from 1 review

Remdesivir for the treatment of COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 562 participants
GRADE not reported

Remdesivir and standard care vs placebo or usual care

All‐cause mortality at up to day 281 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Remdesivir for the treatment of COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.93 [0.81, 1.06]
4 studies · 7142 participants
Moderate